169 related articles for article (PubMed ID: 7448108)
1. An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.
Ellard GA; Jenner PJ; Downs PA
Br J Clin Pharmacol; 1980 Oct; 10(4):369-81. PubMed ID: 7448108
[TBL] [Abstract][Full Text] [Related]
2. Determination of isonicotinic acid in the presence of isoniazid and acetylisoniazid. Studies on isonicotinic acid formation from isoniazid in isolated rat hepatocytes.
Ono Y; Noda A; Zaima Y; Jitsufuchi N; Eto S; Noda H
J Chromatogr B Biomed Appl; 1996 Mar; 677(2):339-43. PubMed ID: 8704939
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.
Seng KY; Hee KH; Soon GH; Chew N; Khoo SH; Lee LS
Antimicrob Agents Chemother; 2015 Nov; 59(11):6791-9. PubMed ID: 26282412
[TBL] [Abstract][Full Text] [Related]
4. A sensitive urine-test method for monitoring the ingestion of isoniazid.
Ellard GA; Greenfield
J Clin Pathol; 1977 Jan; 30(1):84-7. PubMed ID: 838875
[TBL] [Abstract][Full Text] [Related]
5. Participation of P450-dependent oxidation of isoniazid in isonicotinic acid formation in rat liver.
Ono Y; Wu X; Noda A; Noda H; Yoshitani T
Biol Pharm Bull; 1998 Apr; 21(4):421-5. PubMed ID: 9586587
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Amlabu V; Mulligan C; Jele N; Evans A; Gray D; Zar HJ; McIlleron H; Smith P
Int J Tuberc Lung Dis; 2014 May; 18(5):528-30. PubMed ID: 24903787
[TBL] [Abstract][Full Text] [Related]
7. A simplified method for detecting isoniazid compliance in patients receiving antituberculosis chemotherapy.
Hashiguchi M; Ohno K; Sakuma A; Hino F; Tanaka T; Ohtsuji M; Matsumoto N; Yanase K; Urae A; Hosogai Y; Sato N; Yazaki A; Matsuda K; Yamazaki K; Rikihisa T
J Clin Pharmacol; 2002 Feb; 42(2):151-6. PubMed ID: 11831537
[TBL] [Abstract][Full Text] [Related]
8. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Ulanova V; Kivrane A; Viksna A; Pahirko L; Freimane L; Sadovska D; Ozere I; Cirule A; Sevostjanovs E; Grinberga S; Bandere D; Ranka R
Front Pharmacol; 2024; 15():1332752. PubMed ID: 38584604
[No Abstract] [Full Text] [Related]
9. Isoniazid metabolism in the rabbit, and the effect of rifampin pretreatment.
Thomas BH; Wong LT; Zeitz W; Solomonraj G
Res Commun Chem Pathol Pharmacol; 1981 Aug; 33(2):235-47. PubMed ID: 7302372
[TBL] [Abstract][Full Text] [Related]
10. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.
Ellard GA; Gammon PT; Wallace SM
Biochem J; 1972 Feb; 126(3):449-58. PubMed ID: 5075259
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid: metabolic aspects and toxicological correlates.
Preziosi P
Curr Drug Metab; 2007 Dec; 8(8):839-51. PubMed ID: 18220565
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen.
Seth V; Seth SD; Beotra A; Semwal OP; D'monty V; Mukhopadhya S
Indian Pediatr; 1994 Mar; 31(3):279-85. PubMed ID: 7896362
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods.
Sirgel FA; Maritz JS; Venter A; Langdon G; Smith PJ; Donald PR
Int J Pharm; 2006 Jan; 307(2):182-7. PubMed ID: 16303269
[TBL] [Abstract][Full Text] [Related]
14. Ethionamide, prothionamide and thiacetazone self-administration. Studies of patient compliance using isoniazid-marked formulations.
Stanley JN; Pearson JM; Ellard GA
Lepr Rev; 1986 Mar; 57(1):9-18. PubMed ID: 2422517
[No Abstract] [Full Text] [Related]
15. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.
Chen B; Li JH; Xu YM; Wang J; Cao XM
Clin Chim Acta; 2006 Mar; 365(1-2):104-8. PubMed ID: 16182272
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.
Chen B; Shi HQ; Feng MR; Wang XH; Cao XM; Cai WM
Front Pharmacol; 2022; 13():932686. PubMed ID: 35928262
[No Abstract] [Full Text] [Related]
17. Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD
Zhu J; Lu J; Tung HC; Liu K; Li J; Grant DM; Xie W; Ma X
Drug Metab Dispos; 2020 Dec; 48(12):1372-1379. PubMed ID: 33020065
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid metabolism and hepatotoxicity.
Wang P; Pradhan K; Zhong XB; Ma X
Acta Pharm Sin B; 2016 Sep; 6(5):384-392. PubMed ID: 27709007
[TBL] [Abstract][Full Text] [Related]
19. The role of low dosage prothionamide with and without 4,4'-diamino diphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis.
Grosset J; Truffot C; Boval C
Tubercle; 1982 Mar; 63(1):37-43. PubMed ID: 7080212
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid Acetylation Phenotyping in the Japanese: The Molar Metabolic Ratio INH/AcINH.
Kohno H; Kubo H; Takada A; Mori M; Arias TD
Am J Ther; 1996 Jan; 3(1):74-78. PubMed ID: 11856999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
